Immune Monitoring

免疫监测核心将为本计划项目中的所有四个项目提供支持。四 项目涉及单克隆抗体（mAb）或肿瘤疫苗的治疗。MAb（人源化或 嵌合的）或放射性标记的mAb的效力可能由于产生抗mAb的抗体而降低 （哈哈）。某些类型的HAHA可以通过修改mAb设计来避免，需要灵敏的测定 用于鉴定和确定HAHA的精确特异性。癌症疫苗的发展必须 基于可以指导疫苗构建过程的免疫原性测定。在这两种情况下， 如果这些测定是标准化的，并且由集中的、专门的、 设施，允许项目和加班之间的比较。虽然血清学检测足以 监测项目1和2中的mAb研究，还需要T淋巴细胞免疫测定， 是目标3和4中疫苗接种研究的主要焦点。重点是提供分析 项目内部和项目之间以及这些项目与我们以前的经验之间的连续性。一 将使用一系列标准化分析，为各个项目的P.I. S提供坚实的基础， 选择单克隆抗体（mAb）或疫苗用于进一步研究。 具体目标是： 目的1：利用标准化血清学检测来定量对免疫干预的抗体应答 并确定这些抗体的效应子功能。 目的2：利用一系列标准化测定来定量接种疫苗后的T细胞应答， 确定应答T细胞的表型和效应子功能。识别识别的肽 由这些T细胞。 目标3：利用这些集中的标准化检测，在项目内部和项目之间提供连续性 随着时间的推移，这些项目和我们以前的经验之间。 目标4：继续测试和标准化新的试剂或检测，因为它们变得可用。

The Immune Monitoring Core will provide support for all four projects in this Program Project. The four Projects involve treatment with monoclonal antibodies (mAb) or tumor vaccines. MAb (humanized or chimerized) or radiolabeled mAb efficacy may be diminished by development of antibodies against the mAb (HAHA). Some types of HAHA may be avoided by modifications in mAb design, requiring sensitive assays for identifying and determining the precise specificity of the HAHA. Cancer vaccine development must be based on assays of immunogenicity that can guide the process of vaccine construction. In both cases, maximal benefit will result if these assays are standardized and are performed by a centralized, dedicated facility, permitting comparison between Projects and overtime. While serological assays are sufficient for monitoring mAb studies in Projects 1 and 2, assays of T-lymphocyte immunity will also be required and will be the main focus for the vaccination studies in Aims 3 and 4. The emphasis is on providing assay continuity within and between the projects and between these projects and our previous experience. A series of standardized assays will be used to provide the P.l.s of the individual Projects with a firm basis for selecting monoclonal antibodies (mAbs) or vaccines for further study. The Specific Aims are: Aim 1: Utilize standardized serologic assays for quantitating the antibody response to immune interventions in this Program Project, and determine the effector functions of these antibodies. Aim 2: Utilize a series of standardized assays to quantitate the T-cell response after vaccination and to determine the phenotype and effector functions of the responding T-cells. Identify the peptides recognized by these T-cells. Aim 3: Utilize these centralized, standardized assays to provide continuity within and between the Projects over time, and between these Projects and our previous experience. Aim 4: Continue to test and standardize new reagents or assays as they become available.